New Dual-Action Eye Drop Aims to Replace Reading Glasses for Millions

LONDON & SEATTLE – March 30, 2026 – For the 128 million Americans who find themselves stretching their arms to read a menu or squinting at a text message, a new option has arrived that could push their reading glasses aside. Tenpoint Therapeutics, Ltd. today announced the nationwide availability of YUVEZZI™, a prescription eye drop designed to treat presbyopia, the nearly universal age-related loss of close-up vision.

The once-daily drop enters a rapidly evolving market, offering a novel approach to a condition that affects nearly two billion people worldwide. “With the availability of YUVEZZI, we are proud to offer adults with presbyopia a differentiated, one drop, once‑daily eye drop that improves near vision,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, in a statement. The product is now accessible across the United States through both retail pharmacies and the e-pharmacy partner PHILRx.

A New Class of Treatment for an Age-Old Problem

Presbyopia is a natural part of aging, typically beginning around age 45, where the eye’s lens loses its flexibility, making it difficult to focus on nearby objects. For decades, the primary solutions have been mechanical: reading glasses, bifocals, or multifocal contact lenses. However, the last few years have seen a surge in pharmacological innovation, with YUVEZZI marking a significant new milestone.

What sets YUVEZZI apart is its formulation as the first and only FDA-approved dual-agent eye drop for this condition. It combines two active ingredients, carbachol and brimonidine tartrate, that work in synergy to create a “pinhole effect.” Carbachol, a cholinergic agent, constricts the pupil, which sharpens the depth of focus much like a camera aperture. Brimonidine tartrate, an alpha-adrenergic agonist, enhances this effect by relaxing the iris dilator muscle and has the added benefit of reducing eye redness, a common side effect associated with some earlier single-agent eye drops.

This dual mechanism was a key factor in its approval, based on data from two pivotal Phase 3 studies, BRIO I and BRIO II. The trials demonstrated that the combination therapy was superior to using either carbachol or brimonidine alone. A single drop was shown to provide statistically significant improvement in near vision for up to 10 hours, a duration that covers a typical workday and beyond, without a meaningful loss of distance vision.

Navigating a Crowded and Lucrative Market

YUVEZZI’s launch places Tenpoint Therapeutics in a competitive but immensely valuable market. The global presbyopia treatment market is projected to surpass $21 billion by 2032, and pharmaceutical solutions are claiming an ever-larger share. YUVEZZI will compete with other FDA-approved drops, including AbbVie's VUITY, the first-to-market pilocarpine-based drop, and more recent entrants like Orasis Pharmaceuticals' Qlosi and LENZ Therapeutics' VIZZ.

While these competitors have established a foothold, Tenpoint is betting on YUVEZZI’s differentiated profile. “YUVEZZI is designed to help adults see up close more clearly with the ease of a single drop, once-daily dosing, providing a new option for those who want to spend less time searching for reading glasses,” noted Carol Kearney, Chief Commercial Officer of Tenpoint Therapeutics.

Industry analysts believe the extended duration and favorable side effect profile, particularly the lower incidence of eye redness, could be powerful advantages. The company is well-capitalized for the challenge, having recently secured $235 million in combined equity and debt financing to fuel its commercial rollout. This financial backing is intended to support a robust marketing campaign aimed at both eye care professionals and the vast population of potential patients.

From Clinical Trials to Daily Life

For ophthalmologists and optometrists on the front lines of patient care, the arrival of a new, effective tool is welcome. The BRIO II study, described as the longest safety study in presbyopia to date, monitored over 72,000 treatment days and found no treatment-related serious adverse events. The most common side effects were mild and transient, including headache and temporary eye irritation upon use.

“This introduces a novel and intelligent approach to presbyopia correction,” said one ophthalmologist who consults on new ophthalmic technologies. “By combining agents that work on different parts of the pupil control mechanism, you get a more balanced and potent effect. The data suggests a reliable, full-day duration, which is a major factor for patient adherence and satisfaction.”

The ultimate measure of success will be its adoption by patients seeking freedom from the daily frustrations of presbyopia. The convenience of a once-daily drop that allows for spontaneous activities—from reading a price tag at the store to reviewing a report in a dimly lit conference room—is a powerful proposition. As one optometrist noted, “Patients don’t just want to see better; they want their vision to interfere less with their lives. A long-lasting drop can provide that sense of normalcy and freedom.”

The launch of YUVEZZI reflects a broader shift in vision care, where non-invasive, lifestyle-friendly solutions are in high demand. While reading glasses and surgical options will continue to play a role, the growing category of pharmacological treatments offers a compelling middle ground. This new era provides millions of adults with more choices than ever before to manage the inevitable effects of aging on their vision.